169 related articles for article (PubMed ID: 34104608)
41. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial.
Ahmadzadeh A; Seyedian SS; Valizadeh A; Soleimani M; Nazari P; Hamidi H
Asian Pac J Cancer Prev; 2020 Mar; 21(3):727-732. PubMed ID: 32212800
[TBL] [Abstract][Full Text] [Related]
42. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
[TBL] [Abstract][Full Text] [Related]
43. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
44. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
[TBL] [Abstract][Full Text] [Related]
46. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y; Ozdemir N; Colak A; Zengin N
J BUON; 2017; 22(4):919-925. PubMed ID: 29155521
[TBL] [Abstract][Full Text] [Related]
47. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
48. A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients.
Yeh YS; Tsai HL; Ma CJ; Wu DC; Lu CY; Wu IC; Hou MF; Wang JY
Chemotherapy; 2012; 58(5):411-8. PubMed ID: 23306825
[TBL] [Abstract][Full Text] [Related]
49. Different chemotherapy schedules in metastatic colorectal cancer: a response and survival analysis.
Kurteva G; Kurtev P; Krusteva E; Valerianova Z; Boyadjieva L
J BUON; 2002; 7(2):121-5. PubMed ID: 17577274
[TBL] [Abstract][Full Text] [Related]
50. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
[TBL] [Abstract][Full Text] [Related]
51. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity.
Petrelli F; Tomasello G; Ghidini M; Passalacqua R; Barni S
Anticancer Drugs; 2017 Feb; 28(2):133-141. PubMed ID: 27749286
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of FLOT regimen
Farrokhi P; Sadeghi A; Sharifi M; Riechelmann R; Moghaddas A
Res Pharm Sci; 2022 Dec; 17(6):621-634. PubMed ID: 36704436
[TBL] [Abstract][Full Text] [Related]
53. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
54. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I
Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.
Lee HH; Hur H; Kim SH; Park AR; Kim W; Jeon HM
Cancer Res Treat; 2010 Mar; 42(1):18-23. PubMed ID: 20369047
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E
Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753
[TBL] [Abstract][Full Text] [Related]
57. Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
Conteduca V; Gurioli G; Rossi L; Scarpi E; Lolli C; Schepisi G; Farolfi A; De Lisi D; Gallà V; Burgio SL; Menna C; Amadori A; Losi L; Amadori D; Costi MP; De Giorgi U
BMC Cancer; 2018 Dec; 18(1):1267. PubMed ID: 30567527
[TBL] [Abstract][Full Text] [Related]
58. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Zori Comba A; Blajman C; Richardet E; Bella S; Vilanova M; Cóppola F; Van Kooten M; Rodger J; Giglio R; Balbiani L; Perazzo F; Montiel M; Chacón M; Pujol F; Mickiewicz E; Cazap E; Recondo G; Lastiri F; Simon J; Wasserman E; Schmilovich A
Eur J Cancer; 2001 May; 37(8):1006-13. PubMed ID: 11334726
[TBL] [Abstract][Full Text] [Related]
59. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
60. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
